Achillion Pharmaceuticals (NASDAQ:ACHN) Posts Earnings Results, Beats Estimates By $0.02 EPS

Achillion Pharmaceuticals (NASDAQ:ACHN) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02, Fidelity Earnings reports.

NASDAQ ACHN traded up $0.01 on Friday, reaching $6.36. The stock had a trading volume of 1,598,800 shares, compared to its average volume of 2,042,478. The firm has a fifty day moving average of $4.93 and a two-hundred day moving average of $3.79. Achillion Pharmaceuticals has a 1-year low of $1.29 and a 1-year high of $6.46. The company has a market cap of $888.45 million, a P/E ratio of -12.47 and a beta of 1.67.

In other Achillion Pharmaceuticals news, CEO Joseph Truitt sold 133,484 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $6.37, for a total value of $850,293.08. Following the transaction, the chief executive officer now directly owns 103,734 shares of the company’s stock, valued at approximately $660,785.58. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.58% of the company’s stock.

A number of research firms recently weighed in on ACHN. Leerink Swann lowered Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.30 target price on the stock. in a report on Friday, October 18th. Svb Leerink lowered Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and upped their price objective for the company from $5.00 to $6.30 in a report on Friday, October 18th. JMP Securities lowered Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday. Zacks Investment Research lowered Achillion Pharmaceuticals from a “hold” rating to a “sell” rating and set a $4.75 price objective on the stock. in a report on Tuesday, August 27th. Finally, BidaskClub lowered Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, October 12th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $4.96.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

See Also: What is included in the gross domestic product?

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.